NFE2L3 and neoplasm: To achieve NRF3 overexpression, mice were systemically treated with Dox during the tumor formation phase via intraperitoneal injection, and it is unclear if sufficient amounts of Dox reached the ears and for how long it persisted to achieve a stable overexpression.